Akoya Biosciences Stock Revenue
| AKYA Stock | USD 3.22 0.05 1.58% |
Akoya Biosciences fundamentals help investors to digest information that contributes to Akoya Biosciences' financial success or failures. It also enables traders to predict the movement of Akoya Stock. The fundamental analysis module provides a way to measure Akoya Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Akoya Biosciences stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 96.6 M | 68.4 M |
Akoya | Revenue |
Akoya Biosciences Company Revenue Analysis
Akoya Biosciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Akoya Biosciences Revenue | 96.63 M |
Most of Akoya Biosciences' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Akoya Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Akoya
Projected quarterly revenue analysis of Akoya Biosciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Akoya Biosciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Akoya Biosciences' stock price.
Akoya Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Akoya Biosciences is extremely important. It helps to project a fair market value of Akoya Stock properly, considering its historical fundamentals such as Revenue. Since Akoya Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Akoya Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Akoya Biosciences' interrelated accounts and indicators.
| 0.96 | 0.95 | -0.31 | 0.9 | -0.79 | ||
| 0.96 | 0.99 | -0.32 | 0.93 | -0.78 | ||
| 0.95 | 0.99 | -0.43 | 0.91 | -0.67 | ||
| -0.31 | -0.32 | -0.43 | -0.02 | -0.2 | ||
| 0.9 | 0.93 | 0.91 | -0.02 | -0.8 | ||
| -0.79 | -0.78 | -0.67 | -0.2 | -0.8 |
Click cells to compare fundamentals
Akoya Revenue Historical Pattern
Today, most investors in Akoya Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Akoya Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Akoya Biosciences revenue as a starting point in their analysis.
Akoya Biosciences Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Akoya Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Akoya Biosciences reported 96.63 M of revenue. This is 98.73% lower than that of the Health Care Equipment & Supplies sector and 94.74% lower than that of the Health Care industry. The revenue for all United States stocks is 98.98% higher than that of the company.
Akoya Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Akoya Biosciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Akoya Biosciences could also be used in its relative valuation, which is a method of valuing Akoya Biosciences by comparing valuation metrics of similar companies.Akoya Biosciences is currently under evaluation in revenue category among its peers.
Akoya Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Akoya Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Akoya Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Akoya Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Akoya Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Akoya Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Akoya Biosciences' value.| Shares | Northern Trust Corp | 2024-06-30 | 209.7 K | Bridgeway Capital Management, Llc | 2024-06-30 | 179.6 K | Charles Schwab Investment Management Inc | 2024-06-30 | 175.9 K | Gsa Capital Partners Llp | 2024-06-30 | 165.8 K | Osterweis Capital Management Inc | 2024-06-30 | 126.1 K | Bank Of New York Mellon Corp | 2024-06-30 | 67.5 K | Squarepoint Ops Llc | 2024-06-30 | 65.9 K | Zeliff Wallace Jackson Invst Counsel Inc | 2024-09-30 | 45.3 K | Jane Street Group Llc | 2024-06-30 | 44.7 K | Blue Water Life Science Advisors, Llc | 2024-06-30 | 4.7 M | Blackrock Inc | 2024-06-30 | 1.5 M |
Akoya Fundamentals
| Return On Equity | -1.28 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.65) % | ||||
| Operating Margin | (0.47) % | ||||
| Current Valuation | 196.39 M | ||||
| Shares Outstanding | 49.5 M | ||||
| Shares Owned By Insiders | 11.09 % | ||||
| Shares Owned By Institutions | 70.11 % | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Book | 7.05 X | ||||
| Price To Sales | 1.68 X | ||||
| Revenue | 96.63 M | ||||
| Gross Profit | 43.39 M | ||||
| EBITDA | (47.14 M) | ||||
| Net Income | (63.32 M) | ||||
| Cash And Equivalents | 87.61 M | ||||
| Cash Per Share | 2.31 X | ||||
| Total Debt | 85.71 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 3.55 X | ||||
| Book Value Per Share | 0.45 X | ||||
| Cash Flow From Operations | (50.9 M) | ||||
| Short Ratio | 12.91 X | ||||
| Earnings Per Share | (1.17) X | ||||
| Target Price | 4.8 | ||||
| Number Of Employees | 330 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 156.91 M | ||||
| Total Asset | 180.37 M | ||||
| Retained Earnings | (230.07 M) | ||||
| Working Capital | 86.44 M | ||||
| Net Asset | 180.37 M |
About Akoya Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Akoya Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akoya Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akoya Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock:Check out Akoya Biosciences Piotroski F Score and Akoya Biosciences Altman Z Score analysis. For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Revenue Per Share 1.889 | Quarterly Revenue Growth (0.01) | Return On Assets (0.18) | Return On Equity (1.28) |
The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.